whole transcriptome sequencing (Caris Life Sciences)
Structured Review

Whole Transcriptome Sequencing, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/transcriptomic+sequencing/sequencing+transcriptome+whole/pmc13272986-31-12-15
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment"
Article Title: Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment
Journal: Therapeutic Advances in Medical Oncology
doi: 10.1177/17588359261456676
Figure Legend Snippet: Transcriptomic profiling of the pretreatment biopsy sample. RNA-seq was used to obtain gene expression profiles of tumor samples. A global embedding of cancer types was calculated by transforming these gene expression profiles using PCA, followed by a t-SNE transformation to obtain a 2-dimensional approximate “map” of transcriptional similarity. The new patient sample is projected onto a pre-calculated PCA embedding space based on historical samples analyzed at Caris. Its proximity to other samples on the map reflects shared transcriptional programs with these samples. Only the immediate neighborhoods of samples should be considered for further interpretation since t-SNE embeddings do not preserve similarity correlations over long distances. Each point on the t-SNE map represents a different sample. The target symbol represents the present patient’s pretreatment biopsy sample. PCA, principal component analysis; t-SNE, t-stochastic neighbor embedding.
Techniques Used: RNA Sequencing, Gene Expression, Transformation Assay
Related Articles
Sequencing:Article Title: Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2/4 :: CREM fusions Article Snippet: .. For cases 2 and 4, Article Title: Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. Article Snippet: .. Formalinfixed, paraffin-embedded (FFPE) tumor samples (up to 35 slides or the entire tissue block) from each patient were obtained prior to treatment for next-generation whole exome sequencing, while RNA expression analysis of EGFR and c-MET pathways was planned using Formalin-fixed Paraffin-Embedded:Article Title: Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2/4 :: CREM fusions Article Snippet: .. For cases 2 and 4, Article Title: Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. Article Snippet: .. Formalinfixed, paraffin-embedded (FFPE) tumor samples (up to 35 slides or the entire tissue block) from each patient were obtained prior to treatment for next-generation whole exome sequencing, while RNA expression analysis of EGFR and c-MET pathways was planned using other:Article Title: Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations Article Snippet: PURPOSE Themammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs), yet resistance is common, necessitating the identification of resistance mechanisms for effective treatment strategies.. Previous studies suggest that targeting the aberrant expression of mTOR regulators p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyl transferase (NAMPT) sensitizes pNENs to everolimus.. In this study, we queried a large real-world data set of pNENs, characterizing the molecular and immune landscapes, as well as the clinical outcomes associated with aberrant PAK4 and NAMPT expression. Blocking Assay:Article Title: Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. Article Snippet: .. Formalinfixed, paraffin-embedded (FFPE) tumor samples (up to 35 slides or the entire tissue block) from each patient were obtained prior to treatment for next-generation whole exome sequencing, while RNA expression analysis of EGFR and c-MET pathways was planned using RNA Expression:Article Title: Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. Article Snippet: .. Formalinfixed, paraffin-embedded (FFPE) tumor samples (up to 35 slides or the entire tissue block) from each patient were obtained prior to treatment for next-generation whole exome sequencing, while RNA expression analysis of EGFR and c-MET pathways was planned using |

